|
|
Volumn 321, Issue 20, 2019, Pages 2025-2027
|
|
Correction: Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare part D, 2010 to 2019 (JAMA - Journal of the American Medical Association (2019) 321:20 (2025-2027) DOI: 10.1001/jama.2019.4492);Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABIRATERONE;
AFATINIB;
ANTINEOPLASTIC AGENT;
AXITINIB;
BOSUTINIB;
CABOZANTINIB;
CRIZOTINIB;
DABRAFENIB;
DASATINIB;
ENZALUTAMIDE;
ERLOTINIB;
EVEROLIMUS;
GEFITINIB;
IMATINIB;
LAPATINIB;
LENALIDOMIDE;
NILOTINIB;
PAZOPANIB;
POMALIDOMIDE;
PONATINIB;
REGORAFENIB;
RUXOLITINIB;
SORAFENIB;
SUNITINIB;
THALIDOMIDE;
TRAMETINIB;
UNINDEXED DRUG;
VEMURAFENIB;
VISMODEGIB;
VORINOSTAT;
PRESCRIPTION DRUG;
CONSUMER;
DRUG COST;
FINANCIAL MANAGEMENT;
HEALTH CARE ACCESS;
HEALTH CARE POLICY;
HUMAN;
LETTER;
MEDICARE;
PRIORITY JOURNAL;
TREATMENT DURATION;
ECONOMICS;
FEE;
HEALTH CARE COST;
ORAL DRUG ADMINISTRATION;
PUBLICATION;
STATISTICS AND NUMERICAL DATA;
UNITED STATES;
ADMINISTRATION, ORAL;
ANTINEOPLASTIC AGENTS;
FORMULARIES AS TOPIC;
HEALTH EXPENDITURES;
MEDICARE PART D;
PRESCRIPTION DRUGS;
PRESCRIPTION FEES;
UNITED STATES;
|
|
EID: 85066133582
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2019.8629 Document Type: Erratum |
|
Times cited : (79)
|
|
References (5)
|
